^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor) +
    phenformin (mTOR inhibitor, AMPK activator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Cancer Res Commun
    Title:

    Phase Ib trial of phenformin in patients with V600-mutated melanoma receiving dabrafenib and trametinib

    Published date:
    11/06/2023
    Excerpt:
    We conducted a phase Ib dose-escalation trial of phenformin with standard dose dabrafenib/trametinib in patients with metastatic BRAF V600-mutated melanoma….Responses were seen in 10/18 patients overall (56%) and in 2/8 patients who had received prior therapy with RAF inhibitor.
    DOI:
    https://aacrjournals.org/cancerrescommun/article/doi/10.1158/2767-9764.CRC-23-0296/730013/Phase-Ib-trial-of-phenformin-in-patients-with-V600